Testing antibody therapies

A small working group was convened to discuss some of the broad questions and issues arising from the Phase 1 TGN1412 trial in which participants experienced adverse events.

Status: Completed

In March 2006, six volunteers taking part in a phase I clinical trial of a monoclonal antibody, TGN1412, experienced severe adverse events. As part of the Academy's on-going work into the research and development of new medicines, a small working group was convened to discuss some of the broad questions and issues arising from the TGN1412 trial. The project was completed within three months; an example of the Academy responding rapidly to an issue of national importance.   

Horizon Europe participation webinar with AMRC

Book Now

Exploring climate change and health with the next generation of research leaders - invite only two day workshop

Book Now

Future challenges and opportunities for biomedicine in Scotland

Book Now
View more
 
 
 
 
 
 
FB Twitter Instagram Youtube